Intravenous immunoglobulin (IVIG) can reduce the severity of COVID‐19 and TEN/SJS by inhibiting T‐cell activation, IL‐6 and TNF‐ɑ while neutralizing exogenous antigens.7, 22, 24. This evidence concerns the gene TNF and toxic epidermal necrolysis.